Europe
Clinical News
Informatics
Industry News
Practice Management
Education
Subspecialties
More
Sign In
Board Review
CME
Careers
Cases
Conferences
Videos
Webinars
Podcast Network
Advertising
Buyer's Guide
Vendors
Minnies
RPT Tracker
Molecular Imaging Preview
Road to RSNA 2026: Molecular Imaging
By
Will Morton
Molecular imaging highlights this year include a plethora of sessions sharing the latest developments in theranostics and radiotracers.
November 18, 2026
Early F-18 MK-6240 tau PET scans feasible
By
Will Morton
F-18 MK-6240 tau PET scans acquired at 40 to 60 minutes post-injection discriminate Alzheimer disease tau burden as accurately as standard 90- to 120-minute scans, according to research in this session.
November 18, 2026
New PET tracer differentiates cardiac amyloidosis subtypes
By
Will Morton
PET/CT with a novel radiotracer initially developed for amyloid imaging in Alzheimer’s disease may detect and help subtype cardiac amyloidosis, suggest preliminary findings presented in this session.
November 18, 2026
PSMA-PET upstages men with high-risk or recurrent prostate cancer
By
Will Morton
F-18 PSMA PET upstaged nearly four in 10 men with either newly diagnosed high-risk or biochemically recurrent prostate cancer, according to data from a phase III trial being reported in this session.
November 18, 2026
PSMA tracers agree on Pluvicto eligibility, diverge on tumor volume
By
Will Morton
Two U.S.-cleared PSMA PET radiotracers are clinically interchangeable for determining eligibility for Pluvicto treatment in patients with mCRPC, according to research in this session
November 18, 2026
Can an AI model predict Pluvicto treatment response?
By
Erik L. Ridley
An algorithm that combines PSMA-PET imaging features with routine lab values may help predict which patients with mCRPC will respond to Pluvicto radioligand therapy, according to this talk.
November 18, 2026
Post-therapy planar imaging predicts Lutathera response in NETs
By
Will Morton
Whole-body retention measured on post-therapy planar imaging predicts treatment response in patients with neuroendocrine tumors (NETs) receiving Lutathera, according to a presentation in this session.
November 18, 2026
FDG-PET/CT tracks response, guides biopsy in resistant GIST
By
Will Morton
F-18 FDG-PET/CT can monitor treatment response and direct biopsy toward metabolically active lesions in patients with GIST that have stopped responding to standard therapy, researchers will report in this session.
November 18, 2026
FAPI-PET uptake rises with liver fibrosis stage
By
Will Morton
Whole-liver uptake on Ga-68 FAPI PET increased significantly as fibrosis stage worsened in patients with chronic liver disease, according to a prospective study presented in this session.
November 18, 2026
AI predicts survival in metastatic prostate cancer
By
Erik L. Ridley
For patients with metastatic prostate cancer, deep learning applied to PSMA-PET scans may be better for predicting survival than existing risk tools, according to this presentation.
November 18, 2026
Oral PET tracer enables visualization of thoracic duct lymphatic flow
By
Will Morton
An orally administered encapsulated fatty acid radiotracer successfully images thoracic duct lymphatic flow with anatomic precision on PET/CT, suggest preliminary findings from a first-in-human study presented in this session.
November 18, 2026
Do pregnant nuclear medicine trainees need to worry about radiation?
By
Will Morton
Pregnant nuclear medicine resident physicians accumulate radiation doses well below occupational safety limits during training, even under worst-case assumptions, research in this session suggests.
November 18, 2026
Page 1 of 2
Next Page